Contains Nonbinding Recommendations

Guidance on Oxcarbazepine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Oxcarbazepine

Form/Route: Suspension/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 300 mg/5 mL (600 mg dose)
   Subjects: Normal healthy males and females, general population
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 300 mg/5 mL (600 mg dose)
   Subjects: Normal healthy males and females, general population
   Additional comments:

Analytes to measure (in appropriate biological fluid): Oxcarbazepine and its 10-hydroxy metabolite (monohydroxy derivative, MHD) in plasma using an achiral assay.

Bioequivalence based on (90% CI): Oxcarbazepine.
Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please note that a dosage unit for a suspension is the labeled strength (5 ml). A total of 12 units from 12 different bottles should be used.

Finalized May 2008